Document is current
Any future updates will be listed below
-
Authors
Bardon, Ashley R. http://orcid.org/0000-0002-2404-9568
Simoni, Jane M.
Layman, Leif M.
Stekler, Joanne D.
Drain, Paul K.
-
Funding
Funding for this research was provided by:
National Institute of Allergy and Infectious Diseases (AI136648)
Center for AIDS Research, University of Washington (A1027757)
- License Information
-
More Information
Article History
Received: 7 October 2019
Accepted: 29 July 2020
First Online: 6 August 2020
Ethics approval and consent to participate
: All participants provided oral consent prior to participation, and focus group participants used fictitious names to ensure anonymity. The study was approved by the Institutional Review Board at the University of Washington (STUDY00006194).
: Not applicable.
: JDS attended a Gilead Sciences, Inc., advisory board meeting in 2018 and was investigator of record for the participation of the University of Washington AIDS Clinical Trial Unit in ACTU A5305/HPTN 069 (NEXT-PrEP), for which Gilead Sciences, Inc., and ViiV Healthcare provided study medications. PKD reports receiving personal fees from Cepheid and grant support from the National Institutes of Health, the U.S. Centers for Disease Control and Prevention, and the Bill and Melinda Gates Foundation.
